Copyright
©The Author(s) 2015.
World J Gastroenterol. Dec 14, 2015; 21(46): 13087-13094
Published online Dec 14, 2015. doi: 10.3748/wjg.v21.i46.13087
Published online Dec 14, 2015. doi: 10.3748/wjg.v21.i46.13087
Factor | Assignment |
Sex | |
Male | 1 |
Female | 0 |
Age | Age |
Stop treatment | |
Stop | 1 |
Never stop | 0 |
Family history | |
No | 0 |
Unknown | 1 |
Yes | 2 |
Baseline HBeAg | |
HBeAg-negative | 1 |
HBeAg-positive | 0 |
Viral breakthrough | |
Yes | 1 |
No | 0 |
Baseline DNA level (copy/mL) | |
< 104 | 0 |
104-99999 | 1 |
105-999999 | 2 |
≥ 106 | 3 |
Baseline ALT | ALT (IU/mL) |
Diagnose | |
LC | 1 |
CHB | 0 |
- Citation: Su MH, Lu AL, Li SH, Zhong SH, Wang BJ, Wu XL, Mo YY, Liang P, Liu ZH, Xie R, He LX, Fu WD, Jiang JN. Long-term lamivudine for chronic hepatitis B and cirrhosis: A real-life cohort study. World J Gastroenterol 2015; 21(46): 13087-13094
- URL: https://www.wjgnet.com/1007-9327/full/v21/i46/13087.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i46.13087